Moreover, PPAR-γ activation with either rosiglitazone or troglitazone rescued the effects of TGF-β in lung cancer cells, preventing E-cadherin repression and mesenchymal markers upregulation, and thus leading to a reduced mesenchymal-like morphology. Here, CDH1 is linked to lung carcinoma.